当前位置: 首页 > 期刊 > 《新医学》 > 20183
编号:13596829
ANCA相关性血管炎患者的长期临床管理(6)
http://www.100md.com 2018年3月1日 《新医学》 20183
     [26]Faurschou M, Ahlstrm MG, Lindhardsen J, Baslund B, Obel N.Impact of pre-existing co-morbidities on mortality in granulomatosis with polyangiitis: a cohort study.Rheumatology (Oxford),2016,55(4):649-653.

    [27]Mohammad AJ, Segelmark M.A population-based study showing better renal prognosis for proteinase 3 antineutrophil cytoplasmic antibody(ANCA)-associated nephritis versus myeloperoxidase ANCA-associated nephritis. J Rheumatol, 2014,41(7):1366-1373.

    [28]Tanna A, Guarino L, Tam FW, Rodriquez-Cubillo B, Levy JB, Cairns TD, Griffith M, Tarzi RM, Caplin B, Salama AD, Cook T, Pusey CD.Long-term outcome of anti-neutrophil cytoplasm antibody-associated glomerulonephritis: evaluation of the international histological classification and other prognostic factors. Nephrol Dial Transplant,2015,30(7):1185-1192.

    [29]Monach PA, Warner RL, Tomasson G, Specks U, Stone JH, Ding L, Fervenza FC, Fessler BJ, Hoffman GS, Iklé D, Kallenberg CG, Krischer J, Langford CA, Mueller M, Seo P, St Clair EW, Spiera R, Tchao N, Ytterberg SR, Johnson KJ, Merkel PA.Serum proteins reflecting inflammation, injury and repair as biomarkers of disease activity in ANCA-associated vasculitis.Ann Rheum Dis,2013,72(8):1342-1350.

    [30]Haris , Polner K, Arányi J, Braunitzer H, Kaszás I, Mucsi I.Clinical outcomes of ANCA-associated vasculitis in elderly patients.Int Urol Nephrol,2014,46(8):1595-1600., 百拇医药(李倩倩 李胜开)
上一页1 2 3 4 5 6